Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Leo Pharma presents novel VEGFR-2 inhibitors

March 25, 2010

TopoTarget describes new nicotinamide phosphoribosyltransferase inhibitors

March 25, 2010

Pain Therapeutics reports phase I clinical data on PTI-188 in skin cancer

March 24, 2010

EMA's CHMP recommends new Kepivance label in Europe

March 24, 2010

FDA advisory committee: insufficient trial data on pixantrone in relapsed/refractory NHL

March 24, 2010

NCI-sponsored phase I/II trial of Spectrum's belinostat initiated in thymic malignancies

March 24, 2010

Novel VEGFR-2 inhibitors presented by Hutchison MediPharma

March 24, 2010

CyDex begins dosing in phase IIa CDX-353 trial in multiple myeloma

March 23, 2010

Cellceutix signs agreement with Formatech for Kevetrin cancer therapy

March 23, 2010

Molecular Insight advances Solazed for malignant melanoma into phase I trial

March 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...